Catalyst Pharmaceuticals Inc (CPRX)
17.59
+0.22
(+1.27%)
USD |
NASDAQ |
Jul 26, 16:00
17.41
-0.18
(-1.02%)
After-Hours: 20:00
Catalyst Pharmaceuticals Cash from Financing (TTM): 130.04M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 130.04M |
December 31, 2023 | -10.86M |
September 30, 2023 | -7.939M |
June 30, 2023 | 6.172M |
March 31, 2023 | 3.394M |
December 31, 2022 | 1.694M |
September 30, 2022 | -3.085M |
June 30, 2022 | -9.167M |
March 31, 2022 | -9.882M |
December 31, 2021 | -8.143M |
September 30, 2021 | -5.591M |
June 30, 2021 | -2.879M |
March 31, 2021 | 0.864M |
December 31, 2020 | 0.702M |
September 30, 2020 | 1.254M |
June 30, 2020 | 0.8961M |
March 31, 2020 | 1.053M |
December 31, 2019 | 1.116M |
September 30, 2019 | 0.6895M |
June 30, 2019 | 0.5379M |
March 31, 2019 | 0.3494M |
December 31, 2018 | 0.2931M |
September 30, 2018 | 54.28M |
June 30, 2018 | 55.58M |
March 31, 2018 | 57.38M |
Date | Value |
---|---|
December 31, 2017 | 57.35M |
September 30, 2017 | 3.294M |
June 30, 2017 | 1.886M |
March 31, 2017 | 0.0803M |
December 31, 2016 | 0.069M |
September 30, 2016 | 0.0541M |
June 30, 2016 | 0.9708M |
March 31, 2016 | 1.084M |
December 31, 2015 | 37.16M |
September 30, 2015 | 38.92M |
June 30, 2015 | 38.00M |
March 31, 2015 | 64.61M |
December 31, 2014 | 28.56M |
September 30, 2014 | 26.93M |
June 30, 2014 | 44.90M |
March 31, 2014 | 18.20M |
December 31, 2013 | 18.18M |
September 30, 2013 | 23.07M |
June 30, 2013 | 10.67M |
March 31, 2013 | 14.58M |
December 31, 2012 | 14.58M |
September 30, 2012 | 12.81M |
June 30, 2012 | 7.252M |
March 31, 2012 | 3.314M |
December 31, 2011 | 5.543M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-10.86M
Minimum
Dec 2023
130.04M
Maximum
Mar 2024
4.754M
Average
0.702M
Median
Dec 2020
Cash from Financing (TTM) Benchmarks
Vertex Pharmaceuticals Inc | -625.00M |
Sarepta Therapeutics Inc | 45.35M |
PTC Therapeutics Inc | 642.85M |
Regenxbio Inc | 94.80M |
Edgewise Therapeutics Inc | 294.22M |